Company receives grants from the NSF Regenerative Medicine Engine in North Carolina and Greater Winston-Salem Inc. BioNest Fund
GeisterBio, Inc., a U.S. life sciences company founded by Austrian entrepreneur Noah Geister, is expanding its operations in Winston-Salem. Geister founded the company here after visiting the region in March 2025 and experiencing its regenerative medicine research and commercialization ecosystem. Working with an international team, GeisterBio is now building out its local laboratory and quality-control activities with support from a Seed Project Award from the NSF Regenerative Medicine Engine in North Carolina and Greater Winston-Salem Inc.’s BioNest Fund.
GeisterBio’s near-term commercialization initiative, SingleScan, is designed to improve the consistency and quantitative comparability of CT measurements, helping researchers and clinicians generate more reliable imaging data. It is also developing a full-stack biomanufacturing system that produces perfused tissues, with the goal of achieving patient-matched organs like the heart and liver for transplantation.
The company plans to establish a lab and quality control operation at One Technology Place in the Innovation Quarter and make its first two local hires within the first six months. It projects 8-12 jobs over the next three years.
“A location in the Innovation Quarter is strategically important because it places our work near the Wake Forest Institute for Regenerative Medicine, the Regenerative Medicine Engine in North Carolina, the Wake Forest University School of Medicine, and other key partners, while providing access to the regional life-sciences talent and supplier network,” says GeisterBio founder and Chief Executive Officer Noah Geister.
GeisterBio recently received a $250,000 Seed Project Award from the Regenerative Medicine Engine in North Carolina, which supports the development and commercialization of regenerative medicine technologies. The NSF-funded Regenerative Medicine Engine is led by the Wake Forest Institute for Regenerative Medicine (WFIRM) and connects companies with specialized infrastructure, technical expertise, workforce resources, and commercialization support across the region.
The BioNest Fund supports life sciences companies expanding or locating in Winston-Salem and is made possible through the Whitaker Park Development Authority. It fills the gap left when projects in the life sciences sector often don’t qualify for traditional public incentives.
“This project is a great example of the BioNest Fund working hand-in-hand with other resources in the local ecosystem like the Regenerative Medicine Engine to support life sciences companies growing in Winston-Salem. Like many companies, GeisterBio is finding the right fit here,” says Ellis Keifer, Vice President of Economic Development for Greater Winston-Salem Inc.
“GeisterBio’s decision to establish its U.S. operating base in Winston-Salem reflects the growing strength of our life sciences ecosystem and its global reach,” says Isaac Perry, Head of Biotech and Life Science Ecosystem Development for the Innovation Quarter and Greater Winston-Salem Inc. “Companies developing breakthrough technologies are increasingly recognizing the value of locating here, where they can access world-class research institutions, specialized talent, entrepreneurial support, and a collaborative network that helps accelerate innovation and commercialization.”